ArticleOncology letters2019
Expression of integrin α-6 is associated with multi drug resistance and prognosis in ovarian cancer.
Article in Oncology letters, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 19 citations in OpenAlex.
- Integrative Multi-Omics Analysis Reveals HNRNPLL as a Potential Biomarker Associated with Hepatocellular Carcinoma Progression.Metabolites · 2026Article
- Identifying Novel Therapeutic Opportunities for Dilated Cardiomyopathy: A Bioinformatics Approach to Drug Repositioning and Herbal Medicine Prediction.Current pharmaceutical biotechnology · 2026Article
- A novel tumor microenvironment-related gene signature for prognostic prediction of intrahepatic cholangiocarcinoma.Scientific reports · 2025Article
- SNRPB-mediated regulation of DDX39A splicing promotes ovarian cancer progression by regulating α6 integrin subunit expression.Oncogene · 2025Article
- PD-L1Journal of translational medicine · 2025Article
- Development and Perspectives: Multifunctional Nucleic Acid Nanomedicines for Treatment of Gynecological Cancers.Small (Weinheim an der Bergstrasse, Germany) · 2024Review
- Deciphering the Interplay: Thieno[2,3-International journal of molecular sciences · 2024Article
- Platinum-induced upregulation of ITGA6 promotes chemoresistance and spreading in ovarian cancer.EMBO molecular medicine · 2024Article
- Review
- Mechanobiology of cancer cell responsiveness to chemotherapy and immunotherapy: Mechanistic insights and biomaterial platforms.Advanced drug delivery reviews · 2023Review
- Regulation of Kinase Signaling Pathways by α6β4-Integrins and Plectin in Prostate Cancer.Cancers · 2022Review
- Role of integrins in the metastatic spread of high-grade serous ovarian cancer.Archives of gynecology and obstetrics · 2022Article
- Long non-coding RNA OIP5-AS1 suppresses microRNA-92a to augment proliferation and metastasis of ovarian cancer cells through upregulating ITGA6.Journal of ovarian research · 2022Article
- Integrins and Epithelial-Mesenchymal Cooperation in the Tumor Microenvironment of Muscle-Invasive Lethal Cancers.Frontiers in cell and developmental biology · 2022Article
- A Novel Six Autophagy-Related Genes Signature Associated With Outcomes and Immune Microenvironment in Lower-Grade Glioma.Frontiers in genetics · 2021Article
- Diarylpentanoid (1,5-bis(4-hydroxy-3-methoxyphenyl)-1,4-pentadiene-3-one) (MS13) Exhibits Anti-proliferative, Apoptosis Induction and Anti-migration Properties on Androgen-independent Human Prostate Cancer by Targeting Cell Cycle-Apoptosis and PI3K Signalling Pathways.Frontiers in pharmacology · 2021Article
- Bladder Cancer Metastasis Induced by Chronic Everolimus Application Can Be Counteracted by Sulforaphane In Vitro.International journal of molecular sciences · 2020Article
- The Impact of Integrin-Mediated Matrix Adhesion on Cisplatin Resistance of W1 Ovarian Cancer Cells.Biomolecules · 2019Article
- MicroRNA-424 regulates cisplatin resistance of gastric cancer by targeting SMURF1 based on GEO database and primary validation in human gastric cancer tissues.OncoTargets and therapy · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ovarian cancer is a serious threat to women's health. Multidrug resistance is a major cause of post-treatment relapse, metastasis, and even mortality. This characteristic severely restricts the survival of patients with ovarian cancer. Integrin α-6 (ITGA6) is a member of the adhesion molecule family that conducts signals through interactions between the extracellular domain and the matrix, serving important roles in cell adhesion-mediated drug resistance, which is considered to have a critical function in ovarian cancer drug resistance. The association between ITGA6 and ovarian cancer multidrug resistance has been investigated only rarely, to the best of our knowledge. Using RT-qPCR and immunohistochemistry, it was identified that ITGA6 is a central drug resistance gene, and that its expression was upregulated in cisplatin-resistant SKOV3 (SKOV3/DDP2), cisplatin-resistant A2780 (A2780/DDP) cells, and in 54 cases of drug-resistant tissues, as compared with in the controls. Furthermore, bioinformatics and text mining performed by Coremine Medical (http://www.coremine.com/medical/#search) confirmed that ITGA6 was significantly associated with ovarian cancer and drug resistance. Additionally, the high expression of ITGA6 is associated with a poor outcome. The present study provides the basis for further understanding the role of ITGA6 in the regulation of drug resistance in ovarian cancer, and demonstrates that it could be a potential marker for the prognosis of ovarian cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.